Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Receivables (2020 - 2025)

Historic Receivables for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $53.8 million.

  • Xeris Biopharma Holdings' Receivables rose 3066.02% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.8 million, marking a year-over-year increase of 3066.02%. This contributed to the annual value of $40.4 million for FY2024, which is 310.74% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Receivables of $53.8 million as of Q3 2025, which was up 3066.02% from $53.0 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Receivables peaked at $53.8 million during Q3 2025, and registered a low of $13.6 million during Q3 2021.
  • For the 5-year period, Xeris Biopharma Holdings' Receivables averaged around $35.3 million, with its median value being $37.4 million (2024).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Receivables skyrocketed by 15390.55% in 2021 and then tumbled by 1050.34% in 2024.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Receivables stood at $17.5 million in 2021, then soared by 76.62% to $30.8 million in 2022, then increased by 27.14% to $39.2 million in 2023, then increased by 3.11% to $40.4 million in 2024, then skyrocketed by 33.0% to $53.8 million in 2025.
  • Its Receivables stands at $53.8 million for Q3 2025, versus $53.0 million for Q2 2025 and $46.3 million for Q1 2025.